Ivana Yen
Genentech · 65 works · 3,386 citations · h-index 21
Top works
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
- Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling
- Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
- Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase
- Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation
- ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
- Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300
- Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase
- Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase
- Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
- Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study
- Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
- Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice
- 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase
- Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR
- CRAF dimerization with ARAF regulates KRAS-driven tumor growth
- Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase
- Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor
- Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase